Dashenlin
Dashenlin
The company takes the development of pharmacy chain as the foundation of its business
Dashenlin Pharmaceutical Group Co. is a group enterprise integrating pharmaceutical production and sales. The company takes the development of pharmacy chain as the foundation of its business, and after many years of development, at the end of 2015, there were nearly 2,000 directly operated chain stores and nearly 18,000 employees.
- All
- News
- Analysis
- Research
Briefing Jan 19, 2022 05:58 PM
· Healthcare
The China Pavilion of Dubai World Expo ushers in the "Tencent" moment to show the world China's medical innovation and exploration
In depth
Briefing Jan 06, 2022 03:39 PM
· Healthcare
Xinmai medical announced strategic cooperation with rainbow medical, a famous medical device incubator in Israel
Briefing Jan 06, 2022 11:27 AM
· Healthcare
Hengrui medicine has been introduced for more than US $100 million! New antifungal drugs applied for listing in China
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Real Estate, Industrials, FinancialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Real Estate, Industrials, FinancialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Dec 31, 2021 06:27 PM
· Healthcare
The IPO of Lianying medical technology innovation board has been accepted by Shanghai Stock Exchange
Briefing Dec 31, 2021 02:06 PM
· Healthcare
The first KRAS concomitant diagnostic PCR kit in China was approved for marketing
Briefing Dec 31, 2021 02:00 PM
· Healthcare
China's new crown oral drug vv116 has been authorized for emergency use in Uzbekistan
Briefing Dec 31, 2021 01:57 PM
· Healthcare
Wu Kun, chief operating officer of Pfizer China, will leave
In depth
Briefing Dec 31, 2021 01:55 PM
· Healthcare
Samsung Bio said the acquisition of Bojian was untrue
Briefing Dec 30, 2021 08:58 AM
· Healthcare
Jdb175 and jdb153 tablets, a class I new drug of Jiabao Yaoyin, have been approved for clinical trial by China food and drug administration
Briefing Dec 29, 2021 08:03 AM
· Healthcare
Consumer medical SaaS + trading platform Lingjian completed D + round of financing
Healthcare
Dada group's revenue rose nearly 30% in the third quarter, and JD's "hour purchase" cont
Looking forward to the fourth quarter of 2021, dada Group expects its total revenue to be between 2 billion yuan and 2.1 billion yuan. On the premise that the last kilometer of dada express delivery service is consistent with the comparable basis, the total revenue in the fourth quarter of 2021 will achieve a year-on-year increase of 88% to 97%.
Nov 24, 2021 11:42 AM
Briefing Dec 29, 2021 08:03 AM
· Healthcare
Consumer medical SaaS + trading platform Lingjian completed D + round of financing
See more
Related Companies
EqualOcean Analysis
- As Crackdown Looms, Chinese Insurtech Waterdrop Enters Next Growth Phase
- Four Growing Stocks to Watch in the Dynamic Chinese Market
- Digital Health on a Rise: JD Health Stocks Spike 70% on First Trading Day
- Ding Dang Kuai Yao: A Chinese E-Commercial Way to Run a Pharmacy
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.